RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures

Jason H. Mendler; Kati Maharry; Michael D. Radmacher; Krzysztof Mrózek; Heiko Becker; Klaus H. Metzeler; Sebastian Schwind; Susan P. Whitman; Jihane Khalife; Jessica Kohlschmidt; Deedra Nicolet; Bayard L. Powell; Thomas H. Carter; Meir Wetzler; Joseph O. Moore; Jonathan E. Kolitz; Maria R. Baer; Andrew J. Carroll; Richard A. Larson; Michael A. Caligiuri; Guido Marcucci; Clara D. Bloomfield

doi:10.1200/jco.2011.40.6652

Abstract

RUNX1 mutations are twice as common in older than younger patients with CN-AML and negatively impact outcome in both age groups. RUNX1-mutated blasts have molecular features of primitive hematopoietic and lymphoid progenitors, potentially leading to novel therapeutic approaches.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mendler et al. (2012) studied this question.

synapsesocial.com/papers/69df2b143b0ba53fb37a1bd8 https://doi.org/10.1200/jco.2011.40.6652

View at Publisher

Ask AI

Bookmark

Share

RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures

Abstract

Discussion

Cite This Study

RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures

Abstract

Discussion

Cite This Study

Keep reading

Keep reading